AbbVie (ABBV) Notes Payables (2012 - 2025)

AbbVie (ABBV) posted quarterly Notes Payables of $2.5 billion for Q4 2025, down 34.06% quarter-over-quarter from $3.8 billion in Q3 2025.

AbbVie (ABBV) Notes Payables (2012 - 2025) Analysis & Trends

AbbVie (ABBV) has reported Notes Payables for 14 consecutive years, with $2.5 billion the latest figure, recorded in Q4 2025.

In Q4 2025, Notes Payables changed N/A year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $2.5 billion (changed N/A YoY), while the FY2025 annual figure was $2.5 billion, changed N/A from the prior year.
Notes Payables fell to $2.5 billion in Q4 2025 per ABBV's latest filing, from $3.8 billion in the prior quarter.
Across five years, Notes Payables topped out at $3.8 billion in Q3 2025 and bottomed at $1.0 million in Q4 2022.
Historically, Notes Payables has averaged $665.6 million across 5 years, with a median of $14.0 million in 2021.
Annual changes were most pronounced in 2022 — Notes Payables tumbled 92.86% — and 2025, when it surged 53000.0%.
AbbVie's Notes Payables stood at $14.0 million in 2021, then sank by 92.86% to $1.0 million in 2022, then surged by 100.0% to $2.0 million in 2023, then jumped by 50.0% to $3.0 million in 2024, then surged by 83200.0% to $2.5 billion in 2025.
Business Quant data shows ABBV's Notes Payables at $2.5 billion in Q4 2025, $3.8 billion in Q3 2025, and $2.0 billion in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn

Download Data